As of 12:34pm ET
| +0.05 / +3.23%|
Rexahn Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The firm have three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
|Peter David Suzdak||Chief Executive Officer & Director|
|Douglas J. Swirsky||President & Chief Financial Officer|
|Ely Benaim||Chief Medical Officer|
|Lisa M. Nolan||Chief Business Officer|